F-RESCA-RT4
Phase 3Small molecule
F-RESCA-RT4 is one of 113 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1F-RESCA-RT4
RRenJi Hospital
Phase 3
Voltaren
NovartisPreclinical
Tricor
JJagotec
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Gadolinium-Chelate
MM.D. Anderson Cancer Center
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Calcium Channel Blocker
MMinia University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-RESCA-RT4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRenJi Hospital